Biotech is back in 2026… we hope!
When I was crafting the 2026 Year In Review in August, we were nearing all-time-highs in the biotech equity markets… then we hit real turbulence in the fall with the downward pressure of a risk-off trade (when “degrossing” entered the vernacular for many). That backdrop made for challenging story-telling. That said, even with the recent turbulence, the markets have ripped the last 12-18 months, and significantly outperformed the broader markets (S&P500). And the private capital flows into biotech companies, in the US and globally, have been very healthy by any historic measure.
Two positive themes this year have been the cadence of M&A and opening of the IPO window. On M&A, we’ve seen record-breaking levels of bolt-on acquisitions of both public and private biotechs, which has created significant capital recycling. For IPOs, we’re aiming for 30-35 IPOs by year end, making it a dramatically more active year than 2022-2025; with the rise of Reverse Mergers, collectively we’ll see close to 60 “public debuts” this year by R&D-stage biotech companies.
Stepping back to broader industry themes, 2026 has seen some wonderful new innovative medicines reach approval, and a rich pipeline of new medicines advance in development. And excitement around both China and AI as potential levers to improve the industry’s persistent R&D productivity challenges.
Over the past few weeks, we’ve held our 2026 Atlas Venture Retreat and our Annual General Meeting for our Limited Partners (our investors). It was a privilege to yet again kick off each of these meetings with our 2026 Year In Review.
As I’ve noted in past years, listening at 1.25x+ speed is definitely recommended, and moves through the nearly one hour presentation slightly faster.
For those interested, here’s a library of past Year In Review presentations (2025, 2024, 2023, 2022, 2021, 2020, 2019, 2018).
Important and special thanks again this year to my Atlas colleagues Aimee Raleigh, Stella Paffenholz, and Kristen Margeson, who were instrumental in helping me pull it together, and to GoodLab for the design work.
I’d also like to thank all of our friends in the industry who helped provide data supporting this talk, including Cambridge Associates, Cantor, Centerview, Citi, Citeline, Cowen, Evercore, Gilmartin Group, Goldman Sachs, IQVIA, Jefferies, JP Morgan, Leerink, LifeSci Capital, McKinsey, Morgan Stanley, Pitchbook, First Citizens/SVB, Stifel, and others (listed in alphabetical order).




